title: Treatment of Ph1-positive chronic myelogenous leukemia in children: comparison between allogeneic bone marrow transplantation and conventional chemotherapy. Spanish Working Party for BMT in Children (GETMON).
abstract: OBJECTIVE
  To compare the estimated survival and disease-free survival between children with Ph1-positive chronic myeloid leukemia treated with allogeneic bone marrow transplantation or conventional chemotherapy.
  
  
  METHODS
  In this retrospective study we compared the results obtained in a group of 14 children who received allogeneic bone marrow transplantation (BMT) between 1983 and 1993, and another group of 27 children treated with busulfan, hydroxyurea or alpha-interferon during the same time period. Patients were transplanted at a median of 7 months from diagnosis and all except one were in their first chronic phase. Conditioning consisted in total body irradiation and cyclophosphamide in 12 cases, and busulfan was added in two.
  
  
  RESULTS
  Of the 14 patients treated with BMT, two died of transplant-related complications and two relapsed 18 and 48 months after the BMT. Ten children remain alive and disease free at a median follow up of 60 months. The probability of DFS at 5 years is 70%. Of the 27 patients treated with chemotherapy, 22 have died at a median of 36 months from diagnosis. The probability of survival at 5 years is 5% versus 83% for the BMT group (p = 0.001).
  
  
  CONCLUSIONS
  Allogeneic BMT is a safe and very effective treatment for Ph-positive CML in children. Patients who have an HLA-identical sibling donor must receive a transplant as soon as possible after being diagnosed.
authors.affiliation: Department of Pediatrics, Ramón y Cajal Hospital, Madrid, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Muñoz
authors.forename: E
authors.initials: E
authors.lastname: Bureo
authors.forename: J J
authors.initials: JJ
authors.lastname: Ortega
authors.forename: C
authors.initials: C
authors.lastname: Richard
authors.forename: T
authors.initials: T
authors.lastname: Olivé
authors.forename: M S
authors.initials: MS
authors.lastname: Maldonado
authors.forename: L
authors.initials: L
authors.lastname: Madero
authors.forename: M A
authors.initials: MA
authors.lastname: Díaz
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation / Q000401:mortality; D002066:Busulfan / Q000008:administration & dosage; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage; D016898:Interferon-alpha / Q000008:administration & dosage; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000628:therapy*; D015993:Life Tables; D008297:Male; D012074:Remission Induction; D012189:Retrospective Studies; D013030:Spain / Q000453:epidemiology; D016019:Survival Analysis; D019172:Transplantation Conditioning; D016896:Treatment Outcome
chemical_list: D016898:Interferon-alpha; D002066:Busulfan; D006918:Hydroxyurea